Advertisement
EW vs GMED
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EW is a Buy and GMED is a Buy.
EW in upward trend: price rose above 50-day moving average on October 21, 2026
EW moved above its 50-day moving average on October 21, 2026 date and that indicates a change from a downward trend to an upward trend. In 36 of 46 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 78%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on EW as a result. In 55 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 63%.
The Moving Average Convergence Divergence (MACD) for EW just turned positive on October 14, 2026. Looking at past instances where EW's MACD turned positive, the stock continued to rise in 27 of 43 cases over the following month. The odds of a continued upward trend are 63%.
The 10-day moving average for EW crossed bullishly above the 50-day moving average on October 27, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 76%.
Following a +3.99% 3-day Advance, the price is estimated to grow further. Considering data from situations where EW advanced for three days, in 172 of 294 cases, the price rose further within the following month. The odds of a continued upward trend are 59%.
Bearish Trend Analysis
The 10-day RSI Indicator for EW moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In 16 of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at 57%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 11 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EW declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 60%.
EW broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for EW entered a downward trend on October 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 28 (best 1 - 100 worst), indicating outstanding price growth. EW’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 72 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 91 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.995) is normal, around the industry mean (4.201). P/E Ratio (52.879) is within average values for comparable stocks, (1.335). Projected Growth (PEG Ratio) (1.852) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (7.974) is also within normal values, averaging (40.124).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EW’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
GMED's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for GMED turned positive on September 25, 2026. Looking at past instances where GMED's MACD turned positive, the stock continued to rise in 36 of 50 cases over the following month. The odds of a continued upward trend are 72%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on GMED as a result. In 62 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 71%.
GMED moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for GMED crossed bullishly above the 50-day moving average on October 26, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 65%.
Following a +2.48% 3-day Advance, the price is estimated to grow further. Considering data from situations where GMED advanced for three days, in 202 of 310 cases, the price rose further within the following month. The odds of a continued upward trend are 65%.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GMED declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 58%.
GMED broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for GMED entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating steady price growth. GMED’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 60 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 65 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 80 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.198) is normal, around the industry mean (4.201). P/E Ratio (19.660) is within average values for comparable stocks, (1.335). Projected Growth (PEG Ratio) (1.493) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (3.275) is also within normal values, averaging (40.124).
The Tickeron Profit vs. Risk Rating rating for this company is 97 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GMED’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
EW | GMED | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 24 | 75 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 91 Overvalued | 80 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 97 | |
SMR RATING 1..100 | 72 | 65 | |
PRICE GROWTH RATING 1..100 | 28 | 44 | |
P/E GROWTH RATING 1..100 | 8 | 60 | |
SEASONALITY SCORE 1..100 | 50 | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
GMED's Valuation (80) in the Medical Specialties industry is in the same range as EW (91). This means that GMED’s stock grew similarly to EW’s over the last 12 months.
GMED's Profit vs Risk Rating (97) in the Medical Specialties industry is in the same range as EW (100). This means that GMED’s stock grew similarly to EW’s over the last 12 months.
GMED's SMR Rating (65) in the Medical Specialties industry is in the same range as EW (72). This means that GMED’s stock grew similarly to EW’s over the last 12 months.
EW's Price Growth Rating (28) in the Medical Specialties industry is in the same range as GMED (44). This means that EW’s stock grew similarly to GMED’s over the last 12 months.
EW's P/E Growth Rating (8) in the Medical Specialties industry is somewhat better than the same rating for GMED (60). This means that EW’s stock grew somewhat faster than GMED’s over the last 12 months.
| EW | GMED | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 57% | N/A |
| Stochastic ODDS (%) | 2 days ago 52% | 2 days ago 68% |
| Momentum ODDS (%) | 2 days ago 63% | 2 days ago 71% |
| MACD ODDS (%) | 2 days ago 63% | 5 days ago 72% |
| TrendWeek ODDS (%) | 2 days ago 60% | 2 days ago 59% |
| TrendMonth ODDS (%) | 2 days ago 55% | 2 days ago 61% |
| Advances ODDS (%) | 3 days ago 59% | 3 days ago 65% |
| Declines ODDS (%) | 24 days ago 60% | 13 days ago 58% |
| BollingerBands ODDS (%) | 2 days ago 59% | 2 days ago 56% |
| Aroon ODDS (%) | 2 days ago 82% | 2 days ago 59% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
EW’s FA Score shows that 2 FA rating(s) are green while GMED’s FA Score has 0 green FA rating(s).
- EW’s FA Score: 2 green, 3 red.
- GMED’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
EW’s TA Score shows that 5 TA indicator(s) are bullish while GMED’s TA Score has 5 bullish TA indicator(s).
- EW’s TA Score: 5 bullish, 5 bearish.
- GMED’s TA Score: 5 bullish, 4 bearish.
Price Growth
EW (@Medical/Nursing Services) experienced а +3.30% price change this week, while GMED (@Medical/Nursing Services) price change was -4.13% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was +0.04%. For the same industry, the average monthly price growth was -8.74%, and the average quarterly price growth was -9.59%.
Reported Earning Dates
EW is expected to report earnings on Nov 04, 2026.
GMED is expected to report earnings on Nov 05, 2026.
Industries' Descriptions
@Medical/Nursing Services (+0.04% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
Advertisement
GMED and
Correlation & Price change
A.I.dvisor indicates that over the last year, GMED has been loosely correlated with TMCI. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if GMED jumps, then TMCI could also see price increases.
| Ticker / NAME | Correlation To GMED | 1D Price Change % | ||
|---|---|---|---|---|
| GMED | 100% | -5.86% | ||
| TMCI - GMED | 46% Loosely correlated | -12.45% | ||
| TNDM - GMED | 46% Loosely correlated | -3.44% | ||
| MDT - GMED | 45% Loosely correlated | -0.59% | ||
| SYK - GMED | 45% Loosely correlated | -6.38% | ||
| STE - GMED | 44% Loosely correlated | -2.16% | ||
More | ||||